teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 3 Projects Releases Packages Wiki Activity Actions 1

Merge remote-tracking branch 'forgejo/extract/2026-03-22-health-canada-rejects-dr-reddys-semaglutide'

Browse source 
# Conflicts:
#	inbox/archive/health/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md
This commit is contained in:
m3taversal 2026-04-01 16:30:21 +01:00
commit 43fb7442e4
1 changed files with 15 additions and 0 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

15
inbox/archive/health/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md
View file

@ -8,8 +8,13 @@ domain: health
secondary_domains: [] secondary_domains: []
format: news article format: news article
status: processed status: processed
status: enrichment
priority: high priority: high
tags: [semaglutide-generics, glp1, dr-reddys, health-canada, canada, regulatory, patent-cliff, obeda] tags: [semaglutide-generics, glp1, dr-reddys, health-canada, canada, regulatory, patent-cliff, obeda]
processed_by: vida
processed_date: 2026-03-22
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
extraction_model: "anthropic/claude-sonnet-4.5"
--- ---
## Content ## Content
@ -51,3 +56,13 @@ tags: [semaglutide-generics, glp1, dr-reddys, health-canada, canada, regulatory,
PRIMARY CONNECTION: GLP-1 receptor agonists claim ("inflationary through 2035") and the Session 21 claim candidate about Dr. Reddy's 87-country rollout PRIMARY CONNECTION: GLP-1 receptor agonists claim ("inflationary through 2035") and the Session 21 claim candidate about Dr. Reddy's 87-country rollout
WHY ARCHIVED: Corrects the Session 9 projection; establishes regulatory friction as an underappreciated barrier to generic GLP-1 global rollout WHY ARCHIVED: Corrects the Session 9 projection; establishes regulatory friction as an underappreciated barrier to generic GLP-1 global rollout
EXTRACTION HINT: The claim candidate from Session 9 about Dr. Reddy's clearing 87 countries for 2026 rollout needs updating — Canada is NOT in the 2026 timeline. The extractor should flag this as a correction to Session 9's claim candidate 2. EXTRACTION HINT: The claim candidate from Session 9 about Dr. Reddy's clearing 87 countries for 2026 rollout needs updating — Canada is NOT in the 2026 timeline. The extractor should flag this as a correction to Session 9's claim candidate 2.
## Key Facts
- Dr. Reddy's received a non-compliance notice (NoN) from Canada's Pharmaceutical Drugs Directorate in October 2025
- Canada's semaglutide patents expired January 2026
- Dr. Reddy's projected May 2026 Canada launch in its 87-country rollout plan
- Regulatory re-submission and review timeline: 8-12 months minimum
- Dr. Reddy's stated it is 'in constant touch with Canadian regulators' and has 'sent replies to their queries'
- The Canada launch is 'on pause' per company statement
- India launch of Obeda (generic semaglutide) confirmed March 21, 2026